The MENA Gap: Why Clinical Trials for Chronic Inflammatory Diseases Are Falling Short
A recent correspondence in The Lancet Gastroenterology & Hepatology highlights a critical gap in global clinical trial representation, extending the discussion from inflammatory bowel disease to metabolic dysfunction-associated steatotic liver disease. The authors argue that the Middle East and North Africa (MENA) region remains severely under-represented in trials for these chronic, inflammatory conditions, despite their high local prevalence. This disparity creates a significant gap in the applicability of research findings, including those for biologic therapies and novel DMARDs, to MENA populations, underscoring an urgent need for more locally relevant clinical research to ensure global evidence translates into effective regional care.
Study Significance: For rheumatologists and clinical researchers, this underscores a systemic issue in trial design that likely affects autoimmune and inflammatory arthritis studies as well. Ensuring diverse geographic and genetic representation is crucial for validating the efficacy and safety of treatments like JAK inhibitors or TNF blockers across different populations. Addressing this gap is a strategic imperative for developing globally applicable, equitable treatment guidelines and for the accurate assessment of inflammatory markers and disease activity in diverse patient cohorts.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
